Real world patient profile and step up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database Quiz

John is a 72-year-old male with relapsed multiple myeloma, hypertension, and chronic kidney disease stage 3. He is admitted to a large urban teaching hospital to initiate teclistamab therapy with step-up dosing. His current medications include lisinopril 10 mg daily and acetaminophen as needed. The oncology team plans to monitor him closely for adverse events during the inpatient SUD period.

Question: As the clinical pharmacist, which of the following is the most appropriate supportive care regimen to minimize the risk and manage cytokine release syndrome (CRS) during John’s teclistamab step-up dosing?

Maria is a 69-year-old female with relapsed multiple myeloma and peripheral neuropathy. She is scheduled for inpatient initiation of teclistamab with step-up dosing at a teaching hospital with over 300 beds. The oncology team asks the pharmacist about expected hospitalization duration to plan discharge and outpatient follow-up.

Question: Based on real-world data, what is the most accurate estimate of the typical length of hospital stay (LOS) for patients completing teclistamab step-up dosing in this setting?

David is a 75-year-old Black male with relapsed multiple myeloma, anemia, and renal impairment. He is being considered for teclistamab therapy. The oncology pharmacist is reviewing the safety profile and patient characteristics to counsel the care team on expected tolerability and risks.

Question: Which statement best reflects the real-world patient profile and safety outcomes of teclistamab initiation in US hospitals according to recent data?